{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05669833",
            "orgStudyIdInfo": {
                "id": "CNTO1959PSA3006"
            },
            "organization": {
                "fullName": "University of Pennsylvania",
                "class": "OTHER"
            },
            "briefTitle": "Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients",
            "officialTitle": "Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients: a Pragmatic Trial (EVOLUTION)",
            "acronym": "EVOLUTION",
            "therapeuticArea": [
                "Orthopedics"
            ],
            "study": "guselkumab-vs-golimumab-in-psa-tnf-inadequate-responder-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-08",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-07-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-12-20",
            "studyFirstSubmitQcDate": "2022-12-20",
            "studyFirstPostDateStruct": {
                "date": "2023-01-03",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-08-31",
            "lastUpdatePostDateStruct": {
                "date": "2023-09-01",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Pennsylvania",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Janssen Scientific Affairs, LLC",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The trial is a double-blinded randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.",
            "detailedDescription": "The primary aim of the trial will be to determine, among psoriatic arthritis (PsA) patients with an inadequate response (IR) to a tumor necrosis factor inhibitor (TNFi), whether switching to a new mechanism of action (MOA), specifically guselkumab (GUS), a selective interleukin 23 inhibitor (IL23i) targeting the p19 subunit, is more effective than switching to another TNFi. The primary hypothesis of this study is that switching to a new MOA may be more effective than switching to a second TNFi. This will be the first trial to test such a switch in PsA patients. Additionally, the proposed study will address the effectiveness of a new therapy, GUS, in a clinical practice setting among patients who are TNF IR."
        },
        "conditionsModule": {
            "conditions": [
                "Psoriatic Arthritis"
            ],
            "keywords": [
                "Psoriatic Arthritis",
                "PsA"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 300,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "GUS",
                    "type": "EXPERIMENTAL",
                    "description": "Guselkumab (GUS)",
                    "interventionNames": [
                        "Drug: Guselkumab"
                    ]
                },
                {
                    "label": "GUS and Placebo",
                    "type": "EXPERIMENTAL",
                    "description": "Guselkumab (GUS) and Matching Placebo",
                    "interventionNames": [
                        "Drug: Guselkumab",
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "GOL",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Golimumab (GOL)",
                    "interventionNames": [
                        "Drug: Golimumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Guselkumab",
                    "description": "Guselkumab (GUS) subcutaneous injection",
                    "armGroupLabels": [
                        "GUS",
                        "GUS and Placebo"
                    ],
                    "otherNames": [
                        "Tremfya"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Golimumab",
                    "description": "Golimumab (GOL) subcutaneous injection",
                    "armGroupLabels": [
                        "GOL"
                    ],
                    "otherNames": [
                        "Simponi"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Guselkumab (GUS) matching placebo subcutaneous injection",
                    "armGroupLabels": [
                        "GUS and Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Achievement of cDAPSA low disease activity",
                    "description": "Clinical Disease Activity in Psoriatic Arthritis (cDAPSA): a combination score of tender joint count, swollen joint count, patient assessment of pain, and patient global assessment of disease activity. Scale from 0-154 where higher figures indicate worse status. Remission is considered \u22644 and low disease activity \\>4 to \u226413.",
                    "timeFrame": "12 Months"
                },
                {
                    "measure": "Investigator Global Assessment of Psoriasis of Clear or Almost Clear",
                    "description": "Investigator global assessment (IGA) of psoriasis. A scale of 0-4 where higher figures indicate worse status. (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe).",
                    "timeFrame": "12 Months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Minimal Disease Activity (MDA) using PSAID-12",
                    "description": "Minimal Disease Activity (MDA) defines a satisfactory state of disease activity that includes 5 domains of PsA. 5/7 of the following criteria must be satisfied for MDA: patient global \u2264 2 (0-10), patient pain \u2264 2 (0-10), PSAID-12 \\<4 (0-10), TJC (Tender Joint Count) \u2264 1, SJC (Swollen Joint Count) \u2264 1, BSA (Body Surface Area) \u2264 3, and Leeds Enthesitis Index \u2264 1.",
                    "timeFrame": "6 and 12 months"
                },
                {
                    "measure": "Minimal Disease Activity (MDA) using HAQ-DI",
                    "description": "(MDA) Minimal Disease Activity defines a satisfactory state of disease activity that includes 5 domains of PsA. Participant would need to achieve 5/7 of the following criteria: patient global \u2264 2 (0-10), patient pain \u2264 2 (0-10), HAQ-DI (Health Assessment Questionnaire Disability Index) \\< 0.5 (0-3), TJC (Tender Joint Count) \u2264 1, SJC (Swollen Joint Count) \u2264 1, BSA (Body Surface Area) \u2264 3, and Leeds Enthesitis Index \u2264 1.",
                    "timeFrame": "6 and 12 months"
                },
                {
                    "measure": "Change in PSAID-12",
                    "description": "Psoriatic Arthritis Impact of Disease Questionnaire 12-item questionnaire (PSAID-12) Survey. The range of the final PsAID-12 value is 0-10 where higher figures indicate worse status. Negative changes from baseline indicate improvement in disease activity.",
                    "timeFrame": "6 and 12 months"
                },
                {
                    "measure": "PSAID-12 < 4",
                    "description": "Psoriatic Arthritis Impact of Disease Questionnaire 12-item questionnaire (PSAID-12) Survey. The range of the final PsAID-12 value is 0-10 where higher figures indicate worse status.",
                    "timeFrame": "6 and 12 months"
                },
                {
                    "measure": "Change in DLQI",
                    "description": "Dermatology Life Quality Index (DLQI) is a measure of skin disease activity. Calculated score of 0-30 where higher figures indicate worse status.Negative changes from baseline indicate improvement in disease activity.",
                    "timeFrame": "6 and 12 months"
                },
                {
                    "measure": "IGA Among Patients with BSA > 3% at Baseline",
                    "description": "Investigator global assessment (IGA) of psoriasis among patients with BSA (Body Surface Area) \\>3% at baseline. A scale of 0-4 where higher figures indicate worse status. (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe).",
                    "timeFrame": "6 and 12 months"
                },
                {
                    "measure": "IGA Among Patients with IGA \u2265 2 at Baseline",
                    "description": "Investigator global assessment (IGA) of psoriasis among patients with IGA of 2 or more (\u2265 2) at baseline. A scale of 0-4 where higher figures indicate worse status. (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe).",
                    "timeFrame": "6 and 12 months"
                },
                {
                    "measure": "Change in Promis Fatigue",
                    "description": "Promis Fatigue is a measure of fatigue with a score from 8-40 where higher figures indicate worse status. A negative change indicates less overall fatigue.",
                    "timeFrame": "6 and 12 Months"
                },
                {
                    "measure": "Resolution of Dactylitis",
                    "description": "Dactylitis is assessed using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. These results are summed to produce a final score ranging from 0 to 20. A higher score indicates more severe dactylitis. Resolution of dactylitis is defined as a dactylitis score of 0 with a baseline dactylitis score \\>0.",
                    "timeFrame": "6 and 12 Months"
                },
                {
                    "measure": "Resolution of Enthesitis",
                    "description": "Enthesitis is assessed using the Leeds Enthesitis Index (LEI). This measure includes the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The total LEI score of 0-6 is based on evaluating each of these six sites as 0 or 1 based on the absence or presence of pain/tenderness. Resolution of enthesitis is defined as a enthesitis score of 0 with a baseline enthesitis score \\>0.",
                    "timeFrame": "6 and 12 Months"
                },
                {
                    "measure": "Change in BASDAI",
                    "description": "Change in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) among patients with axial disease. The BASDAI sum score ranges from 0 to 10 and higher values indicate more active disease. Negative changes from baseline indicate improvement in disease activity.",
                    "timeFrame": "6 and 12 Months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Psoriatic arthritis meeting CASPAR criteria;\n2. Active psoriatic arthritis defined by the presence of at least 2 swollen joints OR 1 swollen joint and 1 site of active enthesitis OR active dactylitis involving 2 joints\n3. At least one active psoriasis plaque;\n4. Using a TNFi or previously used a single TNFi historically and either never responded or lost response (TNF IR) and planning to switch to a new biologic therapy;\n5. If using a single oral small molecule/csDMARD (i.e., methotrexate, leflunomide, hydroxycloroquine, sulfasalazine, or apremilast), must be on a stable dose for 4 weeks and remain on a stable dose during the study; Only use of a single OSM/csDMARD is allowed.\n6. If using NSAIDs, glucocorticoids (\\<10 mg daily) or topical medications for psoriasis, must be on a stable dose for 4 weeks and remain on a stable dose during the study;\n7. age 18-80\n\nExclusion Criteria:\n\n1. Prior exposure to golimumab or another non-TNFi biologic (IL12/23i, JAKi, an IL17i, or an IL23i);\n2. An adverse event that precludes use of another TNFi (development of drug-induced SLE, allergic reaction, serious infection, heart failure symptoms, demyelination at any point during use of therapy) or any other contraindication or substantial intolerance to a TNFi;\n3. Use of moderate to high dose glucocorticoids (\\>10 mg).\n4. Already meet the primary outcome at screening or baseline\n5. Currently pregnant or actively trying to conceive",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sarah Gillespie",
                    "role": "CONTACT",
                    "phone": "(215) 614-1840",
                    "email": "sarah.hopkins@pennmedicine.upenn.edu"
                },
                {
                    "name": "Study Coordinator",
                    "role": "CONTACT",
                    "email": "SpAProgram@pennmedicine.upenn.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Alexis Ogdie-Beatty, MD, MSCE",
                    "affiliation": "University of Pennsylvania",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Hospital at the University of Pennsylvania",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sarah Gillespie, MS",
                            "role": "CONTACT",
                            "phone": "215-614-1840",
                            "email": "sarah.hopkins@pennmedicine.upenn.edu"
                        },
                        {
                            "role": "CONTACT",
                            "email": "spaprogram@pennmedicine.upenn.edu"
                        },
                        {
                            "name": "Alexis Ogdie-Beatty, MD, MSCE",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001168",
                    "term": "Arthritis"
                },
                {
                    "id": "D000015535",
                    "term": "Arthritis, Psoriatic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007592",
                    "term": "Joint Diseases"
                },
                {
                    "id": "D000009140",
                    "term": "Musculoskeletal Diseases"
                },
                {
                    "id": "D000025242",
                    "term": "Spondylarthropathies"
                },
                {
                    "id": "D000025241",
                    "term": "Spondylarthritis"
                },
                {
                    "id": "D000013166",
                    "term": "Spondylitis"
                },
                {
                    "id": "D000013122",
                    "term": "Spinal Diseases"
                },
                {
                    "id": "D000001847",
                    "term": "Bone Diseases"
                },
                {
                    "id": "D000011565",
                    "term": "Psoriasis"
                },
                {
                    "id": "D000017444",
                    "term": "Skin Diseases, Papulosquamous"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4476",
                    "name": "Arthritis",
                    "asFound": "Arthritis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18178",
                    "name": "Arthritis, Psoriatic",
                    "asFound": "Psoriatic Arthritis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10621",
                    "name": "Joint Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12097",
                    "name": "Musculoskeletal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23036",
                    "name": "Spondylarthropathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M15961",
                    "name": "Spondylitis",
                    "relevance": "LOW"
                },
                {
                    "id": "M23035",
                    "name": "Spondylarthritis",
                    "relevance": "LOW"
                },
                {
                    "id": "M15919",
                    "name": "Spinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5126",
                    "name": "Bone Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14422",
                    "name": "Psoriasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19713",
                    "name": "Skin Diseases, Papulosquamous",
                    "relevance": "LOW"
                },
                {
                    "id": "T5412",
                    "name": "Spondylarthropathy",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC05",
                    "name": "Musculoskeletal Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000529000",
                    "term": "Golimumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000079424",
                    "term": "Tumor Necrosis Factor Inhibitors"
                },
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M150496",
                    "name": "Golimumab",
                    "asFound": "Follow-up Study",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2052",
                    "name": "Tumor Necrosis Factor Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}